GL1X · GenesisL1 explorer

Research workbench

Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo1: an allosterically triggered drug-binding serpin for doxycycline

Analyse Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo1: an… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5OM5
Type
protein
Length
372 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v2 / PDB Bank
Contract
0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
Owner
0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
Resolution
1.595
Source
Homo sapiens
Molecule
Alpha-1-antichymotrypsin
UniProt
P01011
Ligands
CL
Pockets
4 · best druggability 0.60

Structure

x-ray diffraction · resolution 1.595 · 2 distinct chains · 31% helix, 37% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AAlpha-1-antichymotrypsinprotein33834% helix, 36% strandP01011
BAlpha-1-antichymotrypsinprotein340% helix, 47% strandP01011

Ligands and binding sites

  • CL · Chloride ion · ion · chains A, B
  • EDO · 1,2-ethanediol · additive · 3 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1950.600.8726empty
2940.380.7619empty
3640.310.7513empty
4560.250.7317empty

Interfaces

1 interface between chains.

  • A–B · 2555 Ų buried · 36 hydrogen bonds · protein-protein

Compared structures

  • 5OM5 · Crystal structure of ALPHA1-antichymotrypsin variant dbs-I-ALLO1: an allosterically… · the same entry in another collection · chain A against A, TM-score 1.00
  • P01011 · AlphaFold monomer V2.0 prediction for alpha-1-antichymotrypsin (P01011) · a predicted model of the same protein · chain A against A, TM-score 0.92

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.